{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:01:29Z","timestamp":1791910889752,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T00:00:00Z","timestamp":1710892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sonablate"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To characterize patient outcomes following visually directed high-intensity focused ultrasound (HIFU) for focal treatment of localized prostate cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a systematic review of cancer-control outcomes and complication rates among men with localized prostate cancer treated with visually directed focal HIFU. Study outcomes were calculated using a random-effects meta-analysis model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 8 observational studies with 1,819 patients (median age 67\u00a0years; prostate-specific antigen 7.1\u00a0mg\/ml; prostate volume 36\u00a0ml) followed over a median of 24\u00a0months were included. The mean prostate-specific antigen nadir following visually directed focal HIFU was 2.2\u00a0ng\/ml (95% CI 0.9\u20133.5\u00a0ng\/ml), achieved after a median of 6\u00a0months post-treatment. A clinically significant positive biopsy was identified in 19.8% (95% CI 12.4\u201328.3%) of cases. Salvage treatment rates were 16.2% (95% CI 9.7\u201323.8%) for focal- or whole-gland treatment, and 8.6% (95% CI 6.1\u201311.5%) for whole-gland treatment. Complication rates were 16.7% (95% CI 9.9\u201324.6%) for de novo erectile dysfunction, 6.2% (95% CI 0.0\u201319.0%) for urinary retention, 3.0% (95% CI 2.1\u20133.9%) for urinary tract infection, 1.9% (95% CI 0.1\u20135.3%) for urinary incontinence, and 0.1% (95% CI 0.0\u20131.4%) for bowel injury.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Limited evidence from eight observational studies demonstrated that visually directed HIFU for focal treatment of localized prostate cancer was associated with a relatively low risk of complications and acceptable cancer control over medium-term follow-up. Comparative, long-term safety and effectiveness results with visually directed focal HIFU are lacking.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-04840-6","type":"journal-article","created":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T15:02:01Z","timestamp":1710946921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["High-intensity focused ultrasound with visually directed power adjustment for focal treatment of localized prostate cancer: systematic review and meta-analysis"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9211-3680","authenticated-orcid":false,"given":"Samuel J.","family":"Peretsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-0338","authenticated-orcid":false,"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7407-7463","authenticated-orcid":false,"given":"Neil","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6673-9316","authenticated-orcid":false,"given":"Sunao","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0484-801X","authenticated-orcid":false,"given":"Clinton D.","family":"Bahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1594-1885","authenticated-orcid":false,"given":"Larry E.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,20]]},"reference":[{"key":"4840_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"4840_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"4840_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/jnci\/djaa068","volume":"113","author":"A Jemal","year":"2021","unstructured":"Jemal A, Culp MB, Ma J et al (2021) Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening. J Natl Cancer Inst 113:64\u201371","journal-title":"J Natl Cancer Inst"},{"key":"4840_CR4","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1056\/NEJMcibr0905562","volume":"361","author":"HU Ahmed","year":"2009","unstructured":"Ahmed HU (2009) The index lesion and the origin of prostate cancer. N Engl J Med 361:1704\u20131706","journal-title":"N Engl J Med"},{"key":"4840_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1590\/s1677-5538.ibju.2021.0091","volume":"48","author":"A Bakavicius","year":"2022","unstructured":"Bakavicius A, Marra G, Macek P et al (2022) Available evidence on HIFU for focal treatment of prostate cancer: a systematic review. Int Braz J Urol 48:263\u2013274","journal-title":"Int Braz J Urol"},{"key":"4840_CR6","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s10147-020-01847-y","volume":"26","author":"RQ Guo","year":"2021","unstructured":"Guo RQ, Guo XX, Li YM et al (2021) Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis. Int J Clin Oncol 26:461\u2013484","journal-title":"Int J Clin Oncol"},{"key":"4840_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022610","volume":"99","author":"Y He","year":"2020","unstructured":"He Y, Tan P, He M et al (2020) The primary treatment of prostate cancer with high-intensity focused ultrasound: a systematic review and meta-analysis. Medicine (Baltimore) 99:e22610","journal-title":"Medicine (Baltimore)"},{"key":"4840_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.eururo.2021.08.005","volume":"81","author":"JS Hopstaken","year":"2022","unstructured":"Hopstaken JS, Bomers JGR, Sedelaar MJP et al (2022) An updated systematic review on focal therapy in localized prostate cancer: what has changed over the past 5 years? Eur Urol 81:5\u201333","journal-title":"Eur Urol"},{"key":"4840_CR9","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65-94","journal-title":"Ann Intern Med"},{"key":"4840_CR10","unstructured":"National Institute of Health Quality Assessment Tool for before-after (pre-post) studies with no control group. https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools. Accessed 19 Sept 2023"},{"key":"4840_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"4840_CR12","volume-title":"Methods guide for effectiveness and comparative effectiveness reviews","author":"R Fu","year":"2010","unstructured":"Fu R, Gartlehner G, Grant M et al (2010) Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program. Methods guide for effectiveness and comparative effectiveness reviews. Agency for Healthcare Research and Quality, Rockville"},{"key":"4840_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.juro.2018.07.040","volume":"201","author":"R Bass","year":"2019","unstructured":"Bass R, Fleshner N, Finelli A et al (2019) Oncologic and functional outcomes of partial gland ablation with high intensity focused ultrasound for localized prostate cancer. J Urol 201:113\u2013119","journal-title":"J Urol"},{"key":"4840_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.humpath.2021.11.005","volume":"119","author":"K Collins","year":"2022","unstructured":"Collins K, Brocken E, Bahler CD et al (2022) High-intensity focused ultrasound for the treatment of prostate cancer: assessing location of failure after focal therapy in prostate cancer and review of histological characteristics and clinicopathologic correlates after treatment-a 5-year experience. Hum Pathol 119:79\u201384","journal-title":"Hum Pathol"},{"key":"4840_CR15","doi-asserted-by":"publisher","first-page":"489.e9","DOI":"10.1016\/j.urolonc.2022.07.017","volume":"40","author":"YS Khandwala","year":"2022","unstructured":"Khandwala YS, Morisetty S, Ghanouni P et al (2022) Evaluation of post-ablation mpMRI as a predictor of residual prostate cancer after focal high intensity focused ultrasound (HIFU) ablation. Urol Oncol 40:489.e9-489.e17","journal-title":"Urol Oncol"},{"key":"4840_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/jjco\/hym173","volume":"38","author":"S Muto","year":"2008","unstructured":"Muto S, Yoshii T, Saito K et al (2008) Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 38:192\u2013199","journal-title":"Jpn J Clin Oncol"},{"key":"4840_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.eururo.2022.01.005","volume":"81","author":"D Reddy","year":"2022","unstructured":"Reddy D, Peters M, Shah TT et al (2022) Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: a multi-institute 15-year experience. Eur Urol 81:407\u2013413","journal-title":"Eur Urol"},{"key":"4840_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1111\/iju.12876","volume":"22","author":"S Shoji","year":"2015","unstructured":"Shoji S, Nakano M, Fujikawa H et al (2015) Urethra-sparing high-intensity focused ultrasound for localized prostate cancer: functional and oncological outcomes. Int J Urol 22:1043\u20131049","journal-title":"Int J Urol"},{"key":"4840_CR19","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1007\/s10147-020-01723-9","volume":"25","author":"S Shoji","year":"2020","unstructured":"Shoji S, Hiraiwa S, Uemura K et al (2020) Focal therapy with high-intensity focused ultrasound for the localized prostate cancer for Asian based on the localization with MRI-TRUS fusion image-guided transperineal biopsy and 12-cores transperineal systematic biopsy: prospective analysis of oncological and functional outcomes. Int J Clin Oncol 25:1844\u20131853","journal-title":"Int J Clin Oncol"},{"key":"4840_CR20","doi-asserted-by":"publisher","first-page":"7157973","DOI":"10.1155\/2021\/7157973","volume":"2021","author":"CH Yee","year":"2021","unstructured":"Yee CH, Chiu PK, Teoh JY et al (2021) High-intensity focused ultrasound (HIFU) focal therapy for localized prostate cancer with MRI-US fusion platform. Adv Urol 2021:7157973","journal-title":"Adv Urol"},{"key":"4840_CR21","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S1470-2045(12)70121-3","volume":"13","author":"HU Ahmed","year":"2012","unstructured":"Ahmed HU, Hindley RG, Dickinson L et al (2012) Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study. Lancet Oncol 13:622\u2013632","journal-title":"Lancet Oncol"},{"key":"4840_CR22","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.eururo.2015.01.030","volume":"68","author":"HU Ahmed","year":"2015","unstructured":"Ahmed HU, Dickinson L, Charman S et al (2015) Focal ablation targeted to the index lesion in multifocal localised prostate cancer: a prospective development study. Eur Urol 68:927\u2013936","journal-title":"Eur Urol"},{"key":"4840_CR23","doi-asserted-by":"publisher","first-page":"30.e39","DOI":"10.1016\/j.urolonc.2016.07.015","volume":"35","author":"L Dickinson","year":"2017","unstructured":"Dickinson L, Ahmed HU, Hindley RG et al (2017) Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. Urol Oncol 35:30.e39-30.e15","journal-title":"Urol Oncol"},{"key":"4840_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","volume":"74","author":"S Guillaumier","year":"2018","unstructured":"Guillaumier S, Peters M, Arya M et al (2018) A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol 74:422\u2013429","journal-title":"Eur Urol"},{"key":"4840_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1089\/end.2019.0613","volume":"34","author":"PM Huber","year":"2020","unstructured":"Huber PM, Afzal N, Arya M et al (2020) An exploratory study of dose escalation vs standard focal high-intensity focused ultrasound for treating nonmetastatic prostate cancer. J Endourol 34:641\u2013646","journal-title":"J Endourol"},{"key":"4840_CR26","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00345-020-03297-7","volume":"39","author":"PM Huber","year":"2021","unstructured":"Huber PM, Afzal N, Arya M et al (2021) Focal HIFU therapy for anterior compared to posterior prostate cancer lesions. World J Urol 39:1115\u20131119","journal-title":"World J Urol"},{"key":"4840_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.urology.2019.06.043","volume":"133","author":"MJ Johnston","year":"2019","unstructured":"Johnston MJ, Emara A, Noureldin M et al (2019) Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-center in the United Kingdom. Urology 133:175\u2013181","journal-title":"Urology"},{"key":"4840_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bju.15004","volume":"125","author":"CE Lovegrove","year":"2020","unstructured":"Lovegrove CE, Peters M, Guillaumier S et al (2020) Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. BJU Int 125:853\u2013860","journal-title":"BJU Int"},{"key":"4840_CR29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bju.14710","volume":"124","author":"A Stabile","year":"2019","unstructured":"Stabile A, Orczyk C, Hosking-Jervis F et al (2019) Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int 124:431\u2013440","journal-title":"BJU Int"},{"key":"4840_CR30","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/cncr.21999","volume":"107","author":"SH Giordano","year":"2006","unstructured":"Giordano SH, Lee A, Kuo YF et al (2006) Late gastrointestinal toxicity after radiation for prostate cancer. Cancer 107:423\u2013432","journal-title":"Cancer"},{"key":"4840_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/00005392-199907000-00026","volume":"162","author":"IM Thompson","year":"1999","unstructured":"Thompson IM, Middleton RG, Optenberg SA et al (1999) Have complication rates decreased after treatment for localized prostate cancer? J Urol 162:107\u2013112","journal-title":"J Urol"},{"key":"4840_CR32","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.ejca.2005.02.005","volume":"41","author":"AM Meraney","year":"2005","unstructured":"Meraney AM, Haese A, Palisaar J et al (2005) Surgical management of prostate cancer: advances based on a rational approach to the data. Eur J Cancer 41:888\u2013907","journal-title":"Eur J Cancer"},{"key":"4840_CR33","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00345-014-1475-2","volume":"33","author":"BG Muller","year":"2015","unstructured":"Muller BG, van den Bos W, Brausi M et al (2015) Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project. World J Urol 33:1503\u20131509","journal-title":"World J Urol"},{"key":"4840_CR34","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1097\/JU.0000000000000456","volume":"202","author":"M Oishi","year":"2019","unstructured":"Oishi M, Gill IS, Tafuri A et al (2019) Hemigland cryoablation of localized low, intermediate and high risk prostate cancer: oncologic and functional outcomes at 5 years. J Urol 202:1188\u20131198","journal-title":"J Urol"},{"key":"4840_CR35","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.eururo.2012.03.006","volume":"62","author":"D Bahn","year":"2012","unstructured":"Bahn D, de Castro Abreu AL, Gill IS et al (2012) Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol 62:55\u201363","journal-title":"Eur Urol"},{"key":"4840_CR36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00345-017-2130-5","volume":"36","author":"M Kongnyuy","year":"2018","unstructured":"Kongnyuy M, Islam S, Mbah AK et al (2018) PSA kinetics following primary focal cryotherapy (hemiablation) in organ-confined prostate cancer patients. World J Urol 36:209\u2013213","journal-title":"World J Urol"},{"key":"4840_CR37","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/JU.0000000000000298","volume":"202","author":"A Mortezavi","year":"2019","unstructured":"Mortezavi A, Krauter J, Gu A et al (2019) Extensive histological sampling following focal therapy of clinically significant prostate cancer with high intensity focused ultrasound. J Urol 202:717\u2013724","journal-title":"J Urol"},{"key":"4840_CR38","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/j.1464-410X.2006.06509.x","volume":"98","author":"RO Illing","year":"2006","unstructured":"Illing RO, Leslie TA, Kennedy JE et al (2006) Visually directed high-intensity focused ultrasound for organ-confined prostate cancer: a proposed standard for the conduct of therapy. BJU Int 98:1187\u20131192","journal-title":"BJU Int"},{"key":"4840_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12874-021-01310-0","volume":"21","author":"M Geissbuhler","year":"2021","unstructured":"Geissbuhler M, Hincapie CA, Aghlmandi S et al (2021) Most published meta-regression analyses based on aggregate data suffer from methodological pitfalls: a meta-epidemiological study. BMC Med Res Methodol 21:123","journal-title":"BMC Med Res Methodol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04840-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-04840-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-04840-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:24:06Z","timestamp":1735853046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-04840-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4840"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-04840-6","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,20]]},"assertion":[{"value":"23 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Peretsman reports employment with Sonablate. M Emberton serves as a consultant, investigator, and proctor\/educator for Sonacare Inc and Angiodynamics Inc. Neil Fleshner reports no conflicts of interest. Sunao Shoji reports no conflicts of interest. C. Bahler reports consultancy with Sonablate, Telix Pharma, and Early is Good. L. Miller received research support from Sonablate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research did not involve human participants or animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was not applicable, since this was a review of published studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"175"}}